BioCentury
ARTICLE | Company News

Merck, Bionomics deal

June 30, 2014 7:00 AM UTC

Bionomics granted Merck exclusive, worldwide development and commercialization rights to Bionomics’ preclinical BNC375 program, which targets cognitive dysfunction associated with Alzheimer’s disease...